Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue

Jyoti Roy, Karson S. Putt, Domenico Coppola, Marino E. Leon, Farah K. Khalil, Barbara A. Centeno, Noel Clark, Valerie E. Stark, David L. Morse, Philip S. Low

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The expression of cholecystokinin 2 receptor (CCK2R, CCKBR or gastrin receptor) has been reported on a diverse range of cancers such as colorectal, liver, lung, pancreatic, ovarian, stomach, thyroid and numerous neuroendocrine/carcinoid tumors. Some cancers of the colorectum, lung, pancreas and thyroid have been shown to overexpress CCK2R in relation to normal matched tissues of the same organ. This reported overexpression has led to the development of a number of CCK2R-ligand targeted imaging and therapeutic agents. However, no comprehensive study comparing the expression of CCK2R in multiple cancers to multiple normal tissues has been performed. Herein, we report the immunohistochemical analysis of cancer samples from gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and thyroid cancer against multiple normal tissue samples from esophagus, liver, lung, pancreas, stomach, spleen and thyroid. These results show that CCK2R expression is present in nearly all cancer and normal samples tested and that none of the cancer samples had expression that was statistically greater than that of all of the normal samples.

Original languageEnglish (US)
Pages (from-to)14605-14615
Number of pages11
Issue number12
StatePublished - Mar 22 2016


  • CCK2R
  • Cholecystokinin 2 receptor
  • Gastrin receptor

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue'. Together they form a unique fingerprint.

Cite this